Healthgrades Honor Roll Senior Achievement Award - American Academy of Ophthalmology, 2012 Management of vascularized limbal keratitis with prosthetic replacement of the ocular surface system., March 2012 Clinical benefits of the Boston Ocular Surface Prosthesis., Jan 2010 Economic appraisal of the Boston Ocular Surface Prosthesis., Sept 2009 The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab., May 2009 The Effect of Optic Asphericity on Visual Rehabilitation of Corneal Ectasia with a Prosthetic Device, Sept. 2012 Boston Ocular Surface Prosthesis for persistent epitheliopathy after treatment of conjunctival melanoma., April 2010 PROSE treatment of corneal ectasia., May 2012 Bevacizumab for corneal neovascularization., Mar 2009 An ocular surface prosthesis as an innovative adjunct in patients with head and neck malignancy, Oct 2008
Languages:
English Chinese Spanish
Hospitals:
Boston Foundation for Sight 464 Hillside Ave Suite 205, Needham, MA 02494
Beth Israel Deaconess Hospital - Needham 148 Chestnut Street, Needham, MA 02492
Massachusetts General Hospital 55 Fruit Street, Boston, MA 02114
Education:
Medical School Harvard Medical School Graduated: 1987 Medical School Newton Wellesley Hospital Graduated: 1987 Medical School Mass Eye and Ear Infirmary Graduated: 1987
A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance.
A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance.
Perry Rosenthal - Newton MA, US Deborah S. Jacobs - Brookline MA, US
Assignee:
Boston Foundation for Sight - Needham MA
International Classification:
A61M 31/00
US Classification:
604522, 604294
Abstract:
A scleral lens is provided with a drug that is retained in the reservoir of fluid between the scleral lens and the cornea. This system can be used to deliver drugs not currently used because of poor bioavailability, to increase bioavailability of drugs used in patients already wearing a scleral lens, and to improve bioavailability in patients who are not currently wearing the lens. Dosing can be provided less frequently, thus decreasing the risk of non-compliance.
- Needham MA, US Chirag PATEL - Boston MA, US Crystal REMINGTON - Northborough MA, US Alan KWOK - Arlington MA, US Deborah S. JACOBS - Brookline MA, US
International Classification:
G02C 7/04 A61B 3/04
Abstract:
The present disclosure relates to trial scleral lenses, and the resulting scleral lenses, designed for the asymmetric shape of the sclera and/or its chiral properties. In some embodiments, the scleral lenses are also designed for the specific asymmetry associated with different scleral diameters. In addition, as discussed herein, the scleral shape can vary with different conditions of the eye. By designing a set of trial scleral lenses that takes into account these different asymmetric properties of the sclera, a clinician can be more efficient, fitting more eyes with fewer subsequent modifications. The resulting lenses will also achieve a better fit.
- Needham MA, US Chirag PATEL - Boston MA, US Crystal REMINGTON - Northborough MA, US Alan KWOK - Arlington MA, US Deborah S. JACOBS - Brookline MA, US
International Classification:
G02C 7/04 A61B 3/04
Abstract:
The present disclosure relates to trial scleral lenses, and the resulting scleral lenses, designed for the asymmetric shape of the sclera and/or its chiral properties. In some embodiments, the scleral lenses are also designed for the specific asymmetry associated with different scleral diameters. In addition, as discussed herein, the scleral shape can vary with different conditions of the eye. By designing a set of trial scleral lenses that takes into account these different asymmetric properties of the sclera, a clinician can be more efficient, fitting more eyes with fewer subsequent modifications. The resulting lenses will also achieve a better fit.
- Needham MA, US Chirag Patel - Boston MA, US Crystal Remington - Northborough MA, US Alan Kwok - Arlington MA, US Deborah S. Jacobs - Brookline MA, US
International Classification:
G02C 7/04
Abstract:
The present disclosure relates to trial scleral lenses, and the resulting scleral lenses, designed for the asymmetric shape of the sclera and/or its chiral properties. In some embodiments, the scleral lenses are also designed for the specific asymmetry associated with different scleral diameters. In addition, as discussed herein, the scleral shape can vary with different conditions of the eye. By designing a set of trial scleral lenses that takes into account these different asymmetric properties of the sclera, a clinician can be more efficient, fitting more eyes with fewer subsequent modifications. The resulting lenses will also achieve a better fit.
- Needham MA, US Chirag PATEL - Boston MA, US Crystal REMINGTON - Northborough MA, US Alan KWOK - Arlington MA, US Deborah S. JACOBS - Brookline MA, US
International Classification:
G02C 7/04
Abstract:
The present disclosure relates to trial scleral lenses, and the resulting scleral lenses, designed for the asymmetric shape of the sclera and/or its chiral properties. In some embodiments, the scleral lenses are also designed for the specific asymmetry associated with different scleral diameters. In addition, as discussed herein, the scleral shape can vary with different conditions of the eye. By designing a set of trial scleral lenses that takes into account these different asymmetric properties of the sclera, a clinician can be more efficient, fitting more eyes with fewer subsequent modifications. The resulting lenses will also achieve a better fit.
Name / Title
Company / Classification
Phones & Addresses
Deborah Jacobs Partner
Deborah Jacobs Colleges, Universities, and Professional Scho...
P.o. Box 690343, Quincy, MA 02169
Deborah S. Jacobs Medical Doctor
Boston Foundation for Sight Medical Practice · Nonprofit Trust Management · Advancement of Sight Restoration · Ophthalmology
464 Hillside Ave SUITE 205, Needham, MA 02494 1244 Boylston St, Boston, MA 02467 629 Hammond St, Boston, MA 02467 7817267337, 7817267333
Deborah S. Jacobs Medical Doctor, Ophthalmology
Boston Eye Assoc Business Services · Optometrist's Office
464 Hillside Ave #205, Needham Heights, MA 02494 7817267333
Deborah S. Jacobs
Jacobs, Dr. Deborah S Ophthalmology
464 Hillside Ave, Needham Heights, MA 02494 7817267333
Deborah K Jacobs
SJW, ENTERPRISES, INC
Deborah Jacobs Treasurer
J & D TOOLS, INC
337 Bay Rd, North Easton, MA 02356 North Easton, MA 02356
Deborah A. Jacobs Secretary
NEW ENGLAND AU PAIR, INC
17 Rdg Hl Dr, Hanover, MA 02339 86 Grn St, Norwell, MA 02061
This app provides an essential toolfor police accountability, said ACLU-NJ executive director Deborah Jacobs saidin a statement. Too often incidents of serious misconduct go unreportedbecause citizens dont feel that they will be believed. Here, the technologyempowers citizens to place a chec
Date: Jul 05, 2012
Category: U.S.
Source: Google
Post Wedding Update: Zuck Ups Privacy Settings; No More Views of Toy Dog
The couple dated for nine years before the wedding. They met at Harvard University when Facebook was in its early phases. The timing of the ceremony post-Facebook IPO keeps Zuckerbergs billions in proceeds out of community property according to Forbes staff writer, Deborah Jacobs.
Payne "was a principled leader whose legacy will live on in the freedoms that we enjoy," said Deborah Jacobs, executive director of the New Jersey chapter of the American Civil Liberties Union. "We were proud to have Congressman Payne represent New Jersey and remain grateful for his many years of pu